Elias Zerhouni, President of Sanofi R&D, wins 'Executive of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
447
Elias Zerhouni, President of Sanofi R&D, wins 'Executive of the Year' at annual Scrip Awards

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)

Elias Zerhouni, President of Sanofi R&D, wins 'Executive of the Year' at annual Scrip Awards               ·                  Dr. Zerhouni credited with transforming Sanofi's R&D into a high performing organization

PARIS, FRANCE - November 30, 2017 - Elias Zerhouni, M.D., President of Sanofi R&D was awarded 'Executive of the Year' at the 13th Annual Scrip Awards in London last night. 

Dr. Zerhouni was recognized for displaying exemplary leadership in his field by a panel of senior healthcare experts from across the world. He was commended for his role in the transformation of Sanofi's Research & Development operation into one of the highest performing in the industry.

"I am honored to have been awarded this prestigious award, alongside such a distinguished shortlist," said Elias Zerhouni. "This award recognizes the agility and dedication of the extraordinary women and men who work in Research and Development at Sanofi. I am proud of the work we continue to do on behalf of patients to identify and bring to market new therapies of high clinical value."

Dr. Zerhouni joined Sanofi in 2011 and put in place a strategy that first strengthened Sanofi's development function, making it now one of the most efficient in pharma.  He then focused on raising the level of scientific research expertise within the organization, targeting key therapeutic areas including diabetes, cardiovascular, rare diseases, multiple sclerosis, oncology, immunology and infectious diseases with vaccines. Since his appointment, the company has secured 13 new drug approvals.

About Elias Zerhouni, M.D.

Elias Zerhouni was appointed President Sanofi R&D in January 2011 Prior to joining Sanofi, Dr. Zerhouni held the positon of Director of the National Institutes of Health (NIH) of the United States of America from 2002 to 2008. In November 2009, Dr. Zerhouni was appointed one of the first presidential U.S. science envoys by President Obama.

Dr. Zerhouni spent his academic career at Johns Hopkins University and Hospital where he was professor of Radiology and Biomedical engineering. He has authored over 200 publications, holds eight patents and has founded or co-founded 5 start-up companies.  He is also a member of the U.S. National Academy of Medicine and U.S. National Academy of Engineering, received the prestigious Legion of Honor medal from the French National Order in 2008, and was elected in 2010 as a member of the French Academy of Medicine and appointed as Chair of Innovation at the College de France in 2011.

  About Sanofi   Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.   With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.   Sanofi, Empowering Life
  Media Relations Contact Kyra Obolensky Tel. : +33 (0)1 53 77 46 46 mr@sanofi.com      
Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...5770004826

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Dell Technologies: A Fresh Look at Investor Sentiment Trends

Updated Category News Views 285

Understanding Investor Sentiment for Dell Technologies Dell Technologies's recent report provides insight into the company's short interest metrics, illustrating a decline of 14.71%. Currently, 17.41 million shares are sold short, which represents about 5.8% of the company's available shares for trading. With an average trading volume indicating it would take 2.78 days to...

Continue Reading
Compass Diversified Faces Investigation for Securities Violations

Updated Category News Views 173

Compass Diversified Investigates Securities Fraud Claims Compass Diversified (NYSE: CODI) is currently facing serious allegations relating to violations in securities laws. An investigation has been initiated to determine the validity of these claims and how they may affect investors. This situation has raised alarms in the investment community as stakeholders seek...

Continue Reading
Understanding the Dow Inc. Class Action Lawsuit Opportunities

Updated Category News Views 226

Understanding the Dow Inc. Class Action Lawsuit Opportunities Investors in Dow Inc. (NYSE: DOW) have a significant opportunity to take action due to a recent class action lawsuit against the company. This legal movement stems from allegations regarding Dow's disclosure practices and possible financial mismanagement. People who purchased or acquired securities within a...

Continue Reading
Growth Prospects of the Global Medical Imaging Reagents Market

Updated Category News Views 148

Overview of the Medical Imaging Reagents Market The medical imaging reagents market is on the verge of significant growth, projected to reach USD 19.31 billion by 2034. This growth, at a compound annual growth rate (CAGR) of 5.1%, reflects the increasing importance of imaging technologies in healthcare. Key Drivers of Market Growth Several factors are driving this...

Continue Reading
Mike Tyson Teams Up with GBank Financial in New Venture

Updated Category News Views 285

GBank Financial Holdings Inc. Welcomes Mike Tyson GBank Financial Holdings Inc. is excited to announce a significant partnership with the legendary Mike Tyson. This strategic collaboration marks a new chapter for GBank, as Tyson steps in as both a strategic investor and promotional partner for the innovative company, BoltBetz. This new partnership aims to revolutionize...

Continue Reading